- Home
- BIAF vs ALBT Comparison
BIAF vs ALBT Comparison
Compare BIAF & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- ALBT
- Stock Information
- Founded
- BIAF 2014
- ALBT 2014
- Country
- BIAF United States
- ALBT United States
- Employees
- BIAF N/A
- ALBT N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIAF Health Care
- ALBT Health Care
- Exchange
- BIAF Nasdaq
- ALBT Nasdaq
- Market Cap
- BIAF 7.6M
- ALBT 7.4M
- IPO Year
- BIAF 2022
- ALBT N/A
- Fundamental
- Price
- BIAF $0.16
- ALBT $2.69
- Analyst Decision
- BIAF Hold
- ALBT
- Analyst Count
- BIAF 1
- ALBT 0
- Target Price
- BIAF N/A
- ALBT N/A
- AVG Volume (30 Days)
- BIAF 12.0M
- ALBT 78.8K
- Earning Date
- BIAF 11-13-2025
- ALBT 11-11-2025
- Dividend Yield
- BIAF N/A
- ALBT N/A
- EPS Growth
- BIAF N/A
- ALBT N/A
- EPS
- BIAF N/A
- ALBT N/A
- Revenue
- BIAF $7,681,059.00
- ALBT $1,159,091.00
- Revenue This Year
- BIAF N/A
- ALBT N/A
- Revenue Next Year
- BIAF $20.04
- ALBT N/A
- P/E Ratio
- BIAF N/A
- ALBT N/A
- Revenue Growth
- BIAF 4.99
- ALBT N/A
- 52 Week Low
- BIAF $0.16
- ALBT $1.87
- 52 Week High
- BIAF $2.26
- ALBT $11.66
- Technical
- Relative Strength Index (RSI)
- BIAF 34.12
- ALBT 60.94
- Support Level
- BIAF $0.24
- ALBT $2.61
- Resistance Level
- BIAF $0.45
- ALBT $2.90
- Average True Range (ATR)
- BIAF 0.03
- ALBT 0.20
- MACD
- BIAF -0.01
- ALBT 0.06
- Stochastic Oscillator
- BIAF 7.50
- ALBT 79.66
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.